LONDON, March 7,
2023 /PRNewswire/ -- Virax Biolabs Group Limited
("Virax" or the "Company") (Nasdaq: VRAX), an innovative
diagnostics company focused on the prevention, detection, and
diagnosis of viral diseases, announced today that it has entered
into an agreement for the distribution of an Avian Influenza A
Virus ("AIV") real-time PCR test kit to markets accepting the CE
mark, namely the European Union. The test kit is for the detection
and differentiation of ribonucleic acid from AIV and the H5, H7 and
H9 subtypes, including the H5N1 strain currently spreading in
Europe.
The test kit is for use in laboratory settings and can help
healthcare professionals accurately identify an AIV infection. It
also serves as a valuable initial screening test for individuals
that have been exposed to AIV infected livestock or a high-risk
environment. The specialized diagnostic kit can be found by
contacting the company's sales representatives.
Human infections with AIV have occurred in many countries,
predominately after exposure to infected poultry or
virus-contaminated environments. Six main hemagglutinin subtypes of
bird flu viruses have infected people and have resulted in
mild-to-severe illness with a wide range of symptoms and
complications. These six subtypes include H3, H5, H6, H7, H9, and
H10 viruses. Among these, H5N1 and H7N9 viruses have caused the
majority of infections which occur in humans.
Virax's Chairman of the Board of Directors and Chief Executive
Officer, James Foster commented, "We continue to expand
our ViraxClear distribution platform to bring test solutions to a
widening range of viral threats. With a real-time PCR test kit
poised to accurately and reliably detect AIV, including the deadly
H5N1 strain, we expect to facilitate rapid and potentially
life-saving interventions especially in vulnerable
jurisdictions."
About Virax Biolabs Group Limited
Founded in 2013, Virax Biolabs Group Limited is an innovative
diagnostics company focused on the prevention, detection and
diagnosis of viral diseases, with a particular interest in the
field of immunology.
In addition to distributing an array of viral test kits in
unique geographies, Virax Biolabs Group Limited is currently
developing a proprietary T-Cell Test technology with the intention
of providing an immunology profiling platform that assesses each
individual's immune risk profile against major global viral
threats. T-Cell testing can be particularly effective in the
diagnosis and therapeutics of COVID-19 as well as other threats
including Monkeypox, Hepatitis B, Malaria, Herpes and Human
Papillomavirus.
For more information, please visit www.viraxbiolabs.com.
Caution Concerning Forward Looking Statements:
This press release contains forward-looking statements. In
addition, from time to time, we or our representatives may make
forward-looking statements orally or in writing. We base these
forward-looking statements on our expectations and projections
about future events, which we derive from the information currently
available to us. Such forward-looking statements relate to future
events or our future performance, including: our financial
performance and projections; our growth in revenue and earnings;
and our business prospects and opportunities. You can identify
forward-looking statements by those that are not historical in
nature, particularly those that use terminology such as "may,"
"should," "expects," "anticipates," "contemplates," "estimates,"
"believes," "plans," "projected," "predicts," "potential," or
"hopes" or the negative of these or similar terms. In evaluating
these forward-looking statements, you should consider various
factors, including: our ability to change the direction of the
Company; our ability to keep pace with new technology and changing
market needs; and the competitive environment of our business.
These and other factors may cause our actual results to differ
materially from any forward-looking statement. Forward-looking
statements are only predictions. The forward-looking events
discussed in this press release and other statements made from time
to time by us or our representatives, may not occur, and actual
events and results may differ materially and are subject to risks,
uncertainties, and assumptions about us. These forward-looking
statements are based on information currently available to Virax
and its current plans or expectations and are subject to a number
of known and unknown uncertainties, risks and other important
factors that may cause our actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements. These and other important factors are
described in detail in the "Risk Factors" section of Virax's Annual
Report on Form 20-F for the year ended March
31, 2022. Although we believe the expectations reflected in
such forward-looking statements are reasonable, we can give no
assurance that such expectations will prove to be correct. We are
not obligated to publicly update or revise any forward-looking
statement, whether as a result of uncertainties and assumptions,
the forward-looking events discussed in this press release and
other statements made from time to time by us or our
representatives might not occur.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/virax-biolabs-group-limited-introduces-avian-influenza-a-virus-real-time-pcr-test-kit-301764203.html
SOURCE Virax Biolabs